Taro Pharmaceutical Industries
TARO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.62B
Close$
$30.70
28.6% downside
Current Fair Value
28.6% downsideOvervalued by 28.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.62 Billion |
|---|---|
| Enterprise Value | $1.25 Billion |
| Earnings per Share | $1.43 |
| Beta | 0.56 |
| Outstanding Shares | 37,584,891 |
Return
| Return on Equity | 3.00% |
|---|---|
| Return on Assets | 2.49% |
| Return on Invested Capital | 1.22% |
Valuation & Multiples
| P/E Ratio | 30.05 |
|---|---|
| PEG | 25.44 |
| Price to Sales | 2.69 |
| Price to Book Ratio | 0.91 |
| Enterprise Value to Revenue | 1.99 |
| Enterprise Value to EBIT | 57.07 |
| Enterprise Value to Net Income | 23 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Taro Pharmaceutical Industries
CEO: Uday Baldota
